HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

Institute of Pathology, Locarno 6600, Switzerland.
British Journal of Cancer (Impact Factor: 4.82). 01/2013; 108(3). DOI: 10.1038/bjc.2013.4
Source: PubMed

ABSTRACT Background:
In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify additional predictive markers, we investigated the importance of HER2, the primary EGFR dimerisation partner, in this particular disease.

We evaluated the HER2 gene status by fluorescence in situ hybridisation (FISH) in 170 KRAS wild-type mCRC patients treated with cetuximab or panitumumab.

Depending on HER2 gene copy number status, patients showed three distinct cytogenetic profiles: 4% of patients had HER2 gene amplification (R:HER2/CEP17⩾2) in all neoplastic cells (HER2-all-A), 61% of patients had HER2 gain due to polysomy or to gene amplification in minor clones (HER2-FISH+*), and 35% of patients had no or slight HER2 gain (HER2-FISH−). These subgroups were significantly correlated with different clinical behaviours, in terms of response rate (RR; P=0.0006), progression-free survival (PFS; P<0.0001) and overall survival (OS; P<0.0001). Patients with HER2-all-A profile experienced the worst outcome, patients with HER2-FISH− profile showed an intermediate behaviour and patients with HER2-FISH+* profile were related to the highest survival probability (median PFS in months: 2.5 vs 3.9 vs 7.6, respectively; median OS in months: 4.2 vs 9.7 vs 13, respectively).

HER2 gene copy number status may influence the clinical response to anti-EGFR-targeted therapy in mCRC patients.

Download full-text


Available from: Vittoria Martin, May 28, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background To investigate whether MicroRNAs (MiRNAs) are predictive for sensitivity to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer (mCRC) patients. Methods A total of 183 mCRC from two independent cohorts (cohort 1: 74 cases; validation cohort: 109 cases) treated with cetuximab/panitumumab were included onto the study. MiRNA arrays were analysed using Agilent’s miRNA platform. Results The study identified the cluster miR-99a/Let7c/miR-125b as associated with different outcome to anti-EGFR therapies. In the first cohort, patients with high signature had a significantly longer progression free survival (PFS, 6.1 versus 2.3 months, p=0.02) and longer overall survival (OS, 29.8 versus 7.0 months, p=0.08) than patients with low signature. In the validation cohort, patients with high signature had a significantly longer PFS and OS than individuals with low signature (PFS 7.8 versus 4.3 months, p=0.02; OS 12.8 versus 7.5 months, p=0.02). In the KRAS wild-type population (N=120), high signature patients had a significantly longer PFS (7.8 versus 4.6 months, p=0.016) and longer OS (16.1 versus 10.9 months, p=0.09) than low signature individuals, with no difference in KRAS mutated patients. Conclusions MiR-99a/Let7c/miR-125b signature may improve selection of KRAS wild-type mCRC patients candidate for anti-EGFR therapy.
    Clinical Colorectal Cancer 01/2013; DOI:10.1016/j.clcc.2013.11.006 · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with colorectal cancer (CRC) with wild-type KRAS mutations are often treated with the endothelial growth factor receptor (EGFR) monoclonal antibody cetuximab. Despite the presence of a specific molecular target, most patients still do not derive benefit from this biological treatment. Our study explores the role of ephrin A2 (EphA2) receptor expression and of EGFR pathway mediators as predictors of cetuximab benefit. Formalin-fixed paraffin-embedded (FFPE) tumor biopsy samples from 226 cetuximab-treated patients with CRC were studied for mRNA expression of insulin growth factor binding protein 2 (IGFBP2), insulin growth factor receptor 1 (IGF1R), cMET, EphA2, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 by means of TaqMan reverse-transcribed polymerase chain reaction (RT-PCR). Of the 226 patients evaluable for exploratory analysis, 222 had complete data from follow-up visits. The univariate analysis revealed the following significant adverse prognostic factors for risk of death: high EphA2 mRNA levels (hazard ratio [HR], 1.61; P = .015), high HER2 mRNA levels (HR, 1.51; P = .045), and high IGF1R mRNA levels (HR, 1.56; P = .021). Low EphA2 tumor expression was significantly associated with objective response to cetuximab therapy. In multivariate analysis of a broad biomarker panel, factors with independent prognostic value included EphA2 mRNA levels (HR, 1.67; P = .029), high amphiregulin (AREG) mRNA levels in KRAS wild-type tumors (HR, 0.17; P < .0001), and high epiregulin (EREG) mRNA levels (HR, 0.38; P = .006). High EphA2 receptor expression in CRC was associated with a worse outcome in patients treated with cetuximab-based therapy. Prospective validation in treated and control patients is required to dissect the predictive from prognostic role in advanced CRC.
    Clinical Colorectal Cancer 09/2013; 12. DOI:10.1016/j.clcc.2013.07.001 · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clinical entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations. Human EGFR2 (or HER2) has an established role as a prognostic and predictive factor in breast cancer. Although HER2 deregulation, including overexpression, amplification and mutation, has been described in NSCLC, its role as a therapy biomarker remains undefined. In the last few years, there has been a growing interest on HER2 mutation, with few anecdotal or retrospective studies suggesting a relevant role for this biomarker. This review discusses the prognostic and predictive impact of HER2 deregulation and the clinical implications of anti-HER2 strategies in NSCLC.
    Expert Review of Anti-infective Therapy 10/2013; 13(10):1219-28. DOI:10.1586/14737140.2013.846830 · 2.28 Impact Factor
Show more